Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildacerfont in PCOS with elevated adrenal androgens
NCT05370521Phase 2Terminated
- Sponsor
- Spruce Biosciences, Inc.
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing Tildacerfont with Placebo (2 arms). Primary endpoint: Change in Dehydroepiandrosterone Sulfate at 12 weeks. Started May 2022; status: terminated.
02
Drugs
tildacerfont
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT05370521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370521.